TEVA-CHLORPROMAZINE TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE)

Disponible depuis:

TEVA CANADA LIMITED

Code ATC:

N05AA01

DCI (Dénomination commune internationale):

CHLORPROMAZINE

Dosage:

100MG

forme pharmaceutique:

TABLET

Composition:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 100MG

Mode d'administration:

ORAL

Unités en paquet:

100/500/1000

Type d'ordonnance:

Prescription

Domaine thérapeutique:

PHENOTHIAZINES

Descriptif du produit:

Active ingredient group (AIG) number: 0106167002; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2011-03-08

Résumé des caractéristiques du produit

_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 1 of 18_
PRODUCT MONOGRAPH
PR
TEVA-CHLORPROMAZINE
Chlorpromazine Hydrochloride Tablets
25 mg, 50 mg and 100 mg
Teva Standard
Antipsychotic–Antiemetic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Preparation:
December 11, 2012
SUBMISSION CONTROL NO: 154593
_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 2 of 18_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
REFERENCES
..............................................................